Filgrastim: 6 agencies, 2008–2019
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused filgrastim: all 19 decisive outcomes across 6 agencies were positive or positive with restrictions.
Assessment has run over 10.5 years, from 10 Dec 2008 at HAS (France) to 26 Jun 2019 at HAS (France).
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2019; on this evidence the file is dormant.
4 distinct indication wordings are recorded for filgrastim by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 27 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess filgrastim, on 10 Dec 2008; PBAC (Australia) did not open a file until 2018 — an unusually long tail of 9.6 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 9 years in total.
5 of the 6 agencies here assessed filgrastim more than once, HAS (France) most often at 11 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for filgrastim.
The full ledger for filgrastim reads 19 recommended, 5 other, 2 not assessed and 1 deferred.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 26 Jun 2019 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2018 | Chemotherapy-induced neutropenia;Mobilisation of peripheral blood progenitor cells;Assisting bone marrow transplantation;Assisting autologous peripheral blood progenitor … | The PBAC deferred making a recommendation on this submission to seeking further informatio… | source |
| AWMSG (Wales) | 23 Feb 2016 | Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established c… | outside AWMSG criteria | source |
| TLV (Sweden) | 10 Jul 2015 | Accofil ingår i högkostnadsskyddet | general subsidy | source |
| PHARMAC (New Zealand) | 26 Aug 2011 | Neutropenia - autoimmune / congenital / infection-related | PTAC advice: Recommended alteration to access criteria · decision reached | source |
22 further decisions for filgrastim, across 5 agencies, are not shown here. They link to 17 further source documents.
Related molecules
- pegfilgrastim — same ATC class L03A — Immunostimulants
- peginterferon alfa-2a — same ATC class L03A — Immunostimulants
- interferon beta-1a — same ATC class L03A — Immunostimulants
- plerixafor — same ATC class L03A — Immunostimulants
- glatiramer — same ATC class L03A — Immunostimulants
- ropeginterferon alfa-2b — same ATC class L03A — Immunostimulants
Coverage: 27 decisions for filgrastim from 6 agencies, 2008 to 2019. Data to 7 Sep 2026. ATC class L03A — Immunostimulants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.